Recent studies on autoimmune diseases have explored novel anti-CD40L molecules that do not bind to FcγRIIA, such as dapirolizumab, an anti-CD40L antigen-binding fragment (Fab) with a pegylated tail [236], or a monoclonal antibody that lacks the ability to bind to the Fc receptor [237]. Here, CD40LG is linked to autoimmune disease.